Clinical Scorecard: Evaluating the Efficacy of Aromatase Inhibitors Combined with Growth Hormone Therapy in Male Adolescents with Idiopathic Short Stature
At a Glance
Category
Detail
Condition
Idiopathic short stature (ISS) in male adolescents with advanced bone age
Key Mechanisms
Combination of third-generation aromatase inhibitors (letrozole or anastrozole) with recombinant human growth hormone (rhGH) delays bone age progression by inhibiting estrogen synthesis, promoting growth and adult height augmentation
Target Population
Male adolescents aged ≥12 years with ISS, bone age ≥13 years, Tanner stage II or above, height < -2 SD
Care Setting
Pediatric endocrinology outpatient and inpatient settings with regular follow-up every 3 months
Key Highlights
Anastrozole combined with rhGH showed the most significant increase in adult height compared to letrozole or GnRHa combined with rhGH (P < .01).
Adverse monitoring indicators in AI-treated groups normalized after treatment cessation, indicating manageable safety profile.
GnRHa is effective but expensive and requires injections; AIs offer an oral alternative with fewer adverse reactions.
Guideline-Based Recommendations
Diagnosis
Confirm ISS diagnosis by excluding endocrine, genetic, metabolic, and chronic diseases.
Assess bone age (≥13 years) using Tanner–Whitehouse-3 method and sexual maturity (Tanner stage II or above).
Evaluate height < -2 SD for age and target height.
Management
Treat male adolescents with ISS and advanced bone age using rhGH combined with either letrozole or anastrozole.
Consider anastrozole + rhGH for greater adult height augmentation and fewer adverse effects.
Use GnRHa + rhGH as an alternative to delay bone age progression but note higher cost and injection requirement.
Monitoring & Follow-up
Monitor height, height velocity, body weight, and secondary sexual characteristics every 3 months during treatment.
Evaluate bone age every 6 months and perform annual testicular ultrasound and bone mineral density scans.
Discontinue treatment if growth velocity <1 cm over 3 months, near adult height reached, or serious adverse events occur.
Risks
Potential adverse events include liver and kidney dysfunction and fractures; these require treatment discontinuation.
Long-term safety data for AIs in pubescent boys remain limited; off-label use should be carefully considered.
GnRHa treatment is associated with higher cost and injection-related burden.
Patient & Prescribing Data
Male adolescents with ISS, bone age ≥13 years, Tanner stage II or above
Anastrozole combined with rhGH yields superior adult height gains and fewer adverse reactions compared to letrozole or GnRHa combined with rhGH; treatment requires regular monitoring and is discontinued upon reaching growth milestones or adverse events.
Clinical Best Practices
Use propensity score matching to balance treatment groups in clinical studies evaluating ISS therapies.
Regularly monitor growth parameters and hormone profiles to guide treatment duration and safety.
Educate families on treatment options, including benefits and burdens of oral AIs versus injectable GnRHa.
Discontinue therapy promptly upon achieving near adult height or if serious adverse events develop.
An anal fissure masquerading as hemorrhoid pain. A spouse's family history predicting your survival. Melatonin labels lying about their own dosage. This week's studies reward the clinician who looks twice.
